Clear All
12159 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
51662-1514-01 51662-1514 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Mar 31, 2020 In Use
70709-0155-10 70709-0155 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 22, 2025 In Use
67296-1562-03 67296-1562 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan 1, 2018 In Use
47335-0891-72 47335-0891 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb 13, 2014 In Use
57894-0510-01 57894-0510 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 1600.0 mg/10mL, 20000.0 mg/10mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Dec 17, 2025 In Use
85766-0031-25 85766-0031 Methylprednisolone acetate Methylprednisolone acetate 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue Aug 7, 2025 In Use
00002-7716-01 00002-7716 Necitumumab Portrazza 16.0 mg/mL Immunotherapy Monoclonal Antibody EGFR Intravenous Nov 24, 2015 May 27, 2026 In Use
00002-7640-01 00002-7640 Pemetrexed disodium Alimta 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 15, 2008 In Use
57894-0514-01 57894-0514 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 2240.0 mg/14mL, 28000.0 mg/14mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Dec 17, 2025 In Use
00069-1501-30 00069-1501 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jan 31, 2022 Mar 31, 2027 In Use
16714-0671-01 16714-0671 Ondansetron Hydrochloride Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov 28, 2007 Oct 31, 2016 In Use
42291-0155-01 42291-0155 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug 31, 2022 In Use
70518-3458-01 70518-3458 Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate 4.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intralesional, Intramuscular, Intravenous, Soft Tissue Jul 22, 2022 In Use
82959-0111-01 82959-0111 imetelstat sodium RYTELO 188.0 mg/1 Chemotherapy Enzyme Inhibitor Telomerase Intravenous Jun 6, 2024 In Use
31722-0415-14 31722-0415 TEMOZOLOMIDE TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 23, 2024 In Use
42658-0010-01 42658-0010 Cladribine Cladribine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous May 18, 2020 In Use
83634-0779-02 83634-0779 Metoclopramide hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jun 30, 2024 In Use
71335-3042-01 71335-3042 PredniSONE PredniSONE Tablets, USP, 5 mg 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec 3, 2025 In Use
00069-1195-30 00069-1195 talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct 26, 2018 Aug 31, 2027 In Use
46708-0091-10 46708-0091 Triamcinolone Acetonide Triamcinolone Acetonide 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular Oct 17, 2025 In Use
00054-3177-57 00054-3177 Dexamethasone Dexamethasone 0.5 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov 1, 2007 In Use
60505-6439-01 60505-6439 Palonosetron Hydrochloride Palonosetron 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct 31, 2025 In Use
50742-0406-20 50742-0406 Oxaliplatin Oxaliplatin 100.0 mg/20mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct 29, 2018 Mar 31, 2026 In Use
59676-0303-00 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug 8, 2011 In Use
20536-0322-01 20536-0322 Vincristine Sulfate Marqibo Chemotherapy Antimitotic Agent Vinca Alkaloid Jan 14, 2013 Oct 26, 2020 In Use

Found 12159 results — Export these results